Marksans Pharma quarterly results and financials

Marksans Pharma (MARKSANS)₹308.75+1.65%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Marksans Pharma reported sales of ₹843 Cr, up 35.7% from Jun 2025, and net profit of ₹159 Cr, up 174.2% year on year. For the year to Mar 2026, sales were ₹2,954 Cr and net profit ₹421 Cr.

Sales (Jun 2026): ₹843 Cr
Net profit (Jun 2026): ₹159 Cr
Sales (FY Mar 2026): ₹2,954 Cr
Net profit (FY Mar 2026): ₹421 Cr
EPS (Jun 2026): ₹3.48
Borrowings (Mar 2026): ₹342 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Marksans Pharma quarterly results

₹ crore unless stated; each column is a quarter.

Marksans Pharma Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	532	587	561	592	643	684	709	621	721	755	857	843
Expenses	418	454	452	463	497	545	583	522	578	595	663	630
Operating Profit	114	133	110	128	147	139	127	99.99	144	161	195	213
OPM %	21.0%	23.0%	20.0%	22.0%	23.0%	20.0%	18.0%	16.0%	20.0%	21.0%	23.0%	25.0%
Other Income	18.99	4.99	16.99	15.01	0.00	27.99	14.99	5.99	22.01	20.01	35.01	25.01
Interest	1.99	2.99	4.98	2.99	2.99	2.99	2.99	5.98	5.97	5.98	5.98	6.97
Depreciation	18.01	22.01	21.01	20.01	20.02	21.01	23.01	22.99	27.03	23.99	24.01	25.02
Profit before tax	114	113	100	120	125	143	116	77.17	133	151	200	207
Tax %	26.0%	26.0%	22.9%	25.9%	21.9%	27.0%	22.0%	23.9%	26.0%	24.9%	24.9%	23.0%
Net Profit	84.14	83.11	78.09	89.20	98.24	105	91.11	58.13	99.22	114	149	159
EPS (Rs)	1.83	1.83	1.74	1.97	2.14	2.30	1.99	1.28	2.16	2.51	3.28	3.48

Marksans Pharma profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Marksans Pharma Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	895	768	915	1,002	1,137	1,378	1,494	1,856	2,180	2,628	2,954	3,176
Expenses	759	724	836	870	944	1,040	1,235	1,517	1,725	2,095	2,358	2,466
Operating Profit	136	44.99	78.09	132	192	340	259	340	459	533	602	713
OPM %	15.0%	6.0%	9.0%	13.0%	17.0%	25.0%	17.0%	18.0%	21.0%	20.0%	20.0%	22.5%
Other Income	8.99	6.99	8.01	5.01	0.00	7.01	41.99	58.96	49.96	65.99	82.01	102
Interest	9.96	6.98	9.96	9.96	8.97	7.97	7.97	8.97	10.96	11.95	23.92	24.90
Depreciation	28.03	30.01	27.01	23.01	27.01	36.01	45.02	52.04	74.01	83.04	99.02	100
Profit before tax	107	15.01	50.05	104	157	302	248	338	425	505	561	692
Tax %	22.9%	24.0%	28.0%	23.0%	23.0%	21.0%	24.9%	20.9%	25.9%	24.0%	24.9%	—
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	1.01	—
Net Profit	83.13	11.02	36.10	80.10	121	239	187	265	315	383	421	522
EPS (Rs)	1.91	0.23	0.81	1.88	2.96	5.77	4.52	5.87	6.93	8.39	9.23	11.43
Dividend payout %	21.0%	23.0%	6.0%	3.0%	3.0%	4.0%	6.0%	9.0%	9.0%	10.0%	10.0%	—

Marksans Pharma balance sheet

₹ crore, at each year end.

Marksans Pharma Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	41.03	41.04	41.01	41.01	41.05	41.05	41.04	41.04	44.98	45.02	44.98	45.02
Reserves	327	402	393	431	503	597	848	1,165	1,705	2,026	2,427	2,984
Borrowings	101	99.59	110	118	99.65	29.87	33.86	111	122	243	321	342
Other Liabilities	207	179	208	142	160	235	306	322	320	370	449	487
Total Liabilities	677	722	752	732	803	903	1,229	1,638	2,193	2,685	3,242	3,859
Fixed Assets	166	269	266	279	269	302	308	427	485	774	979	1,041
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	11.96	2.99	9.97	8.97	26.93	58.75
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.01	27.05	1.01	0.00
Other Assets	511	453	485	452	534	601	909	1,208	1,698	1,875	2,235	2,759
Inventories	130	168	190	218	293	242	404	424	485	618	846	971
Trade receivables	184	218	249	177	178	244	273	396	418	455	541	648
Cash & equivalents	185	35.08	25.04	40.06	34.04	94.19	212	350	716	675	705	991
Total Assets	677	722	752	732	803	903	1,229	1,638	2,193	2,685	3,242	3,859

Marksans Pharma cash flow

₹ crore, for each year.

Marksans Pharma Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	155	30.98	13.98	49.94	26.98	233	179	98.84	237	230	207	458
Cash from investing activity	−32.94	−123	−20.93	−38.92	−12.96	−59.85	−44.87	−83.74	−258	−141	−48.89	−248
Cash from financing activity	17.05	−58.20	−3.01	3.01	−21.07	−114	−15.04	80.23	199	−69.16	−65.13	−71.20
Net cash flow	138	−150	−9.99	14.99	−6.99	59.97	118	93.93	176	20.99	93.03	138
Capex	36.12	132	28.08	39.08	13.04	60.13	46.10	46.14	54.15	210	173	131
Free cash flow	118	−101	−13.97	10.98	13.96	174	133	52.83	184	21.96	34.93	328
CFO / OP %	108.0%	43.0%	31.0%	73.1%	41.0%	134.0%	67.0%	66.0%	88.0%	77.0%	62.1%	99.0%

Marksans Pharma ratios

Working-capital days and returns, by year.

Marksans Pharma Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	83	88	117	70	63	77	71	96	81	75	74	79
Inventory days	106	119	150	151	214	154	247	215	191	216	269	277
Days payable	87	84	128	53	77	70	102	101	90	93	97	95
Cash conversion cycle	103	124	140	169	202	163	217	211	183	199	247	261
Working capital days	17	59	77	70	97	87	104	121	122	129	142	149
ROCE %	44.0%	23.0%	4.0%	10.0%	18.0%	25.0%	38.0%	23.0%	22.0%	21.0%	20.0%	19.0%

Marksans Pharma: frequently asked questions

What are the latest quarterly results of Marksans Pharma?

For the Jun 2026 quarter, Marksans Pharma reported sales of ₹843 Cr, up 35.7% year on year and net profit of ₹159 Cr, up 174.2% year on year. The operating margin was 25.0%.

What is the annual revenue of Marksans Pharma?

Marksans Pharma's sales for the year to Mar 2026 were ₹2,954 Cr; over the last twelve months they were ₹3,176 Cr.

What is the net profit of Marksans Pharma?

Net profit for the year to Mar 2026 was ₹421 Cr, and ₹522 Cr over the last twelve months. Earnings per share over the same trailing period were ₹11.43.

How much debt does Marksans Pharma have?

Marksans Pharma reported borrowings of ₹342 Cr at Mar 2026, against cash and equivalents of ₹991 Cr.

What is the free cash flow of Marksans Pharma?

Cash from operations was ₹458 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹328 Cr.

Loading…